Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 8/20 | 0.54 |
| ▸ | TAS1R2 | Q8TE23 | 8/20 | 0.54 |
| ▸ | TAS1R1 | Q7RTX1 | 7/20 | 0.54 |
| ▸ | CCR2 | P41597 | 7/20 | 0.47 |
| ▸ | MLYCD | O95822 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | TACR2 | P21452 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13156527 | 1.00 | TAS1R3 (0.54) | TAS1R3TAS1R2TAS1R1CCR2MLYCD | |
| SCHEMBL13156501 | 0.83 | TAS1R3 (0.54) | TAS1R3TAS1R2TAS1R1CCR2MLYCD | |
| SCHEMBL3093182 | 0.83 | TAS1R3 (0.54) | TAS1R3TAS1R2TAS1R1CCR2MLYCD | |
| SCHEMBL13156483 | 0.80 | TAS1R3 (0.54) | TAS1R3TAS1R2TAS1R1CCR2MLYCD | |
| SCHEMBL3084697 | 0.80 | TAS1R3 (0.51) | TAS1R3TAS1R2TAS1R1CCR2MLYCD | |
| SCHEMBL3092278 | 0.80 | TAS1R3 (0.54) | TAS1R3TAS1R2TAS1R1CCR2MLYCD | |
| SCHEMBL13156529 | 0.80 | TAS1R3 (0.51) | TAS1R3TAS1R2TAS1R1CCR2MLYCD | |
| SCHEMBL15956008 | 0.78 | TAS1R3 (0.50) | TAS1R3TAS1R2TAS1R1 | |
| SCHEMBL3101149 | 0.77 | TAS1R3 (0.51) | TAS1R3TAS1R2TAS1R1CCR2MLYCD | |
| SCHEMBL13949743 | 0.77 | TAS1R3 (0.48) | TAS1R3TAS1R2TAS1R1CCR2MLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799934-B2 | Intermediates (synthons) in the synthesis of pharmaceuticals such as oseltamivir and other products; treating the arizidine with the nucleophile in the presence of a biaryl phosphoric acid catalyst | UNIVERSITY OF SOUTH FLORIDA (US) | 2010-09-21 | — | — | US | disclosed |
| US-20090030212-A1 | Enantioselective ring-opening of aziridines | UNIVERSITY OF SOUTH FLORIDA OF TAMPA | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030212-A1 | Enantioselective ring-opening of aziridines | AZI2, ITPA, ADORA2A | TAS1R3 4604/4885TAS1R2 4429/4885TAS1R1 4471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.